patient view
This page is a research summary built from public sources (FDA, NIH, clinical trial registries). It is not medical advice.Always talk to your doctor about treatment decisions. Drug information here may be incomplete or out of date — verify with your prescriber and the manufacturer's package insert.
drug · protein
lutetium Lu 177 dotatate
Marketedupdated 2mo agoby Advanced Accelerator Applications SA🔗 ChEMBL
Approvedcommunity read0 votes
Protein drug with a maximum clinical stage of Approval (across all indications), with an approval for neuroendocrine neoplasm and neuroendocrine carcinoma and 7 investigational indications.
targets
Somatostatin receptor
all catalysts(0)
nothing on the calendar yet
News(1)
- Novartis' radioligand therapy Lutathera could soon face generic competitionThe radioligand field is on the cusp of a major competitive moment, as a rival looks to bring the first generic to a market that’s been dominated by Novartis. Radioligand therapy aims to bring th…endpoints · 2mo ago
comments(0)
5-min edit window · permanent after that